证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 会议资料 二〇二五年九月 目 录 奥精医疗科技股份有限公司 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权 利，确保股东大会的正常秩序和议事效率，根据《公司法》《证券法》《上市公 司股东大会规则》《奥精医疗科技股份有限公司章程》《奥精医疗科技股份有限 公司股东大会议事规则》等有关规定，特制定本会议须知： 一、为保证本次大会的严肃性和正常秩序，除出席会议的股东、董事、监事、 高级管理人员、公司聘任律师及中介机构外，公司有权依法拒绝其他人员入场。 二、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 三、请出席大会的股东或其代理人或其他出席者在会议召开前 30 分钟到达 会场办理签到手续，并请按规定出示证券账户卡、身份证或法人单位证明、企业 营业执照复印件（加盖公章）、授权委托书等，经验证后方可出席会议。 四、本次大会现场会议于 2025 年 9 月 15 日下午 14 点 30 分正式开始，会 议开始后，在会议主持人宣布现场出席会议的股东和代理人 ...

证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年九月 | | | | 2025 | 年第二次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 3 | | 2025 | 年第二次临时股东大会会议议案 | 5 | 四、本次大会现场会议于 2025 年 9 月 15 日下午 14 点 30 分正式开始，会 议开始后，在会议主持人宣布现场出席会议的股东和代理人人数及所持有的表决 权数量之前，会议签到登记应当终止。迟到股东人数、股权数不计入表决数。 奥精医疗科技股份有限公司 2025 年第二次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权 利，确保股东大会的正常秩序和议事效率，根据《公司法》《证券法》《上市公 司股东大会规则》《奥精医疗科技股份有限公司章程》《奥精医疗科技股份有限 公司股东大会议事规则》等有关规定，特制定本会议须知： 一、为保证本次大会的严肃性和正常秩序，除出席会议的股东、董事、监事、 高级管理人员、公司聘任律师及中 ...

Market Performance - The medical device sector increased by 1.33% on September 5, with JinHao Medical leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Top Gainers in Medical Device Sector - JinHao Medical (872925) closed at 31.25, up 10.00% with a trading volume of 31,400 shares and a transaction value of 93.90 million yuan [1] - AoJing Medical (688613) closed at 21.50, up 9.19% with a trading volume of 87,400 shares and a transaction value of 182 million yuan [1] - BoXun Bio (836504) closed at 31.24, up 4.55% with a trading volume of 18,000 shares and a transaction value of 55.51 million yuan [1] Top Losers in Medical Device Sector - JiMin Health (603222) closed at 10.51, down 8.77% with a trading volume of 896,400 shares and a transaction value of 947 million yuan [2] - SaiNuo Medical (688108) closed at 34.18, down 7.25% with a trading volume of 736,700 shares and a transaction value of 246.2 million yuan [2] - TouJing Life (300642) closed at 27.12, down 4.88% with a trading volume of 245,300 shares and a transaction value of 63.9 million yuan [2] Capital Flow in Medical Device Sector - The medical device sector experienced a net outflow of 295 million yuan from institutional investors, while retail investors saw a net inflow of 299 million yuan [2][3] - The top net inflows from retail investors included companies like LePu Medical (300003) with a net inflow of 16.38 million yuan [3]

Group 1 - The company will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [1][2] - Investors can submit questions from September 10 to September 16, 2025, before 16:00, through the Roadshow Center website or via the company's email [3] Group 2 - Key participants in the briefing include Chairman Eric Gang Hu, General Manager and Secretary of the Board Qiu Zhiye, and Chief Financial Officer Wang Ling [2] - After the briefing, investors can view the meeting details and main content on the Shanghai Stock Exchange Roadshow Center [4]

关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688613 证券简称：奥精医疗 公告编号：2025-049 奥精医疗科技股份有限公司 会议召开时间：2025 年 09 月 17 日（星期三） 15:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 09 月 10 日 （星期三） 至 09 月 16 日 （星 期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 information@allgensmed.com 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 奥精医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深 入地了解公司 2025 年半年 ...

Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and performance metrics, with significant changes in shareholder structure and upcoming corporate actions [1][2][3][4]. Stock Performance - As of August 29, 2025, Aojing Medical's stock closed at 20.0 CNY, down 4.4% from the previous week [1]. - The stock reached a high of 21.26 CNY and a low of 19.15 CNY during the week [1]. - The company's current market capitalization is 2.74 billion CNY, ranking 115th in the medical device sector and 4666th in the A-share market [1]. Financial Performance - For the first half of 2025, Aojing Medical reported a main revenue of 100 million CNY, a slight decrease of 0.2% year-on-year [2]. - The net profit attributable to shareholders was 7.9753 million CNY, down 13.52% year-on-year [2]. - The second quarter of 2025 showed a main revenue of 57.5772 million CNY, an increase of 8.88% year-on-year, with a net profit of 6.9338 million CNY, up 203.59% year-on-year [2]. Shareholder Changes - As of June 30, 2025, the number of shareholders increased to 8543, reflecting an 8.07% rise since March 31, 2025 [1]. - The average number of shares held per shareholder decreased from 17,100 to 16,000, with an average holding value of 306,600 CNY [1]. Corporate Announcements - Aojing Medical's second supervisory board meeting on August 29, 2025, approved several key proposals, including the half-year report and the use of idle fundraising for operational needs [3]. - A special shareholders' meeting is scheduled for September 15, 2025, to discuss the re-election of a non-independent director [3]. - BioVeda China RMB Investment Limited, holding 5.28% of the company, plans to reduce its stake by up to 1% between September 22 and December 22, 2025 [4].

Core Insights - Aojing Medical (688613) reported a net profit decline of 13.52% year-on-year for the first half of 2025, with total revenue of 100 million yuan, a slight decrease of 0.2% compared to the previous year [1] - The second quarter showed a revenue increase of 8.88% year-on-year, with a significant net profit increase of 203.59% [1] Financial Performance - Total revenue for 2025 was 100 million yuan, unchanged from 2024, with a net profit of 797.53 million yuan, down 13.52% [1] - Gross margin decreased to 63.12%, down 17.75% year-on-year, while net margin improved to 5.53%, up 12.23% [1] - Total expenses (selling, administrative, and financial) amounted to 52.27% of revenue, a decrease of 13.41% year-on-year [1] Key Metrics - Earnings per share (EPS) decreased to 0.06 yuan, down 14.29% year-on-year, while operating cash flow per share improved to -0.03 yuan, an increase of 55.48% [1] - The company's return on invested capital (ROIC) has been historically low, with a median of 9.28% since its listing, and a particularly poor ROIC of -1.21% in 2024 [3] - The company maintains a healthy cash position, indicating good solvency [3]

Core Viewpoint - BioVeda China RMB Investment Limited plans to reduce its shareholding in Aojing Medical Technology Co., Ltd. due to personal financial arrangements, with a maximum reduction of 1,355,515 shares, representing 1% of the total shares [1] Shareholder Reduction Plan - As of the announcement date, BioVeda holds 7,239,358 shares, accounting for 5.28% of Aojing Medical's total shares [1] - The reduction will occur through centralized bidding and block trading, starting from September 22, 2025, to December 22, 2025 [1] - The reason for the reduction is stated as personal financial arrangements [1] Shareholder Background - BioVeda is identified as a controlling shareholder and holds more than 5% of the shares [1] - In the past 12 months, BioVeda has reduced its holdings by 345,087 shares, representing 0.25% of the total shares, at a price range of 17.00 to 17.19 yuan per share [1] Compliance with Lock-up Commitments - The planned reduction is consistent with previous commitments made by BioVeda regarding the lock-up of shares for 12 months post-IPO [2] - There are no other arrangements or commitments that conflict with the current reduction plan [2]

Summary of Key Points Core Viewpoint - On August 29, Guizhou Moutai announced plans for a significant share buyback, while 13 other listed companies disclosed their intentions to reduce shareholdings [1][2]. Group 1: Guizhou Moutai - The controlling shareholder of Guizhou Moutai intends to increase its stake by purchasing shares worth between 3 billion to 3.3 billion yuan [2]. Group 2: Companies Reducing Holdings - Several companies announced share reductions, including: - Siyi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce its stake by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their stake by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce his stake by up to 0.0615% [2]. - Aorite: Tian Tai Bolong plans to reduce its holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce his stake by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce his holdings by up to 1% [2].

每经AI快讯，奥精医疗（SH 688613，收盘价：20元）8月29日晚间发布半年度业绩报告称，2025年上 半年营业收入约1亿元，同比减少0.2%；归属于上市公司股东的净利润约798万元，同比减少13.52%； 基本每股收益0.06元，同比减少14.29%。 截至发稿，奥精医疗市值为27亿元。 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...